Structural basis of respiratory syncytial virus neutralization by motavizumab.
McLellan, J.S., Chen, M., Kim, A., Yang, Y., Graham, B.S., Kwong, P.D.(2010) Nat Struct Mol Biol 17: 248-250
- PubMed: 20098425 
- DOI: 10.1038/nsmb.1723
- Primary Citation of Related Structures:  
3IXT - PubMed Abstract: 
Motavizumab is approximately tenfold more potent than its predecessor, palivizumab (Synagis), the FDA-approved monoclonal antibody used to prevent respiratory syncytial virus (RSV) infection. The structure of motavizumab in complex with a 24-residue peptide corresponding to its epitope on the RSV fusion (F) glycoprotein reveals the structural basis for this greater potency ...